fig2

From: Effects of DNA topoisomerase IIα splice variants on acquired drug resistance

Figure 2. A novel human TOP2α/90 isoform is overexpressed in acquired resistance to TOP2α-targeted drugs etoposide, mitoxantrone, and amsacrine. A: TOP2α immunoassay utilizing K562 and K/VP.5^{[35,36,55,56]} cell lysates; B: TOP2α immunoassay utilizing HL-60 and HL-60/MX2^[32,50,51] cell lysates; C: TOP2α immunoassay utilizing HL-60 and HL-60/AMSA^[57] cell lysates. The immunoblots were probed with an antibody specific for the N-terminal portion of TOP2α/170 (i.e., amino acids 14-27, denoted N-terminal Ab). (A) Image is from Figure 2A published originally in the Journal of Pharmacology and Experimental Therapeutics; Kanagasabai et al.^[35], 2017. TOP2α: topoisomerase IIα